Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction

NCT06480968 is registered in ClinicalTrials.gov with Connecta Therapeutics, S.L. as lead sponsor.

NCT NCT06480968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06480968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction
Lead sponsor
Connecta Therapeutics, S.L.
Phase
Phase 1
Overall status
Completed
Start date
June 23, 2023
Completion date
November 11, 2024
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome